ストックスクリーナーアプリを入手
9.305
2.54%
0.265
前日終値:
$9.04
開ける：
$8.99
24時間の取引高:
185.91K
Relative Volume:
0.13
時価総額：
$917.32M
収益：
$142.77M
当期純損益:
$-80.04M
株価収益率:
-11.48
EPS:
-0.8103
ネットキャッシュフロー:
$-86.02M
1週間 パフォーマンス:
-0.75%
1か月 パフォーマンス:
-4.14%
6か月 パフォーマンス:
-7.94%
1年 パフォーマンス:
-14.72%
1日の値動き範囲:
$8.98
$9.33
1週間の範囲:
$8.75
$9.38
52週間の値動き範囲:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
名前
Ars Pharmaceuticals Inc
セクター
電話
858-771-9307
住所
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
9.28 | 893.59M | 142.77M | -80.04M | -86.02M | -0.8103 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.37 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.63 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.83 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.11 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.78 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-04 | 再開されました | Roth Capital | Buy |
| 2025-09-04 | 開始されました | Roth Capital | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-10 | 開始されました | Oppenheimer | Outperform |
| 2024-08-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 繰り返されました | Leerink Partners | Outperform |
| 2024-07-25 | 開始されました | Raymond James | Outperform |
| 2024-03-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | 開始されました | William Blair | Outperform |
| 2022-12-13 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
ARS Pharmaceuticals (SPRY) Expected to Announce Earnings on Monday - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY): Analyst Consensus Sees 214% Upside Potential - DirectorsTalk Interviews
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
Raymond James reiterates Strong Buy on ARS Pharmaceuticals stock - Investing.com
SPRY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SPRY PE Ratio & Valuation, Is SPRY Overvalued - Intellectia AI
ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded at Zacks Research - MarketBeat
Can Growing Patient And Provider Adoption Of Neffy Propel ARS Pharma's Stock Upward? - Nasdaq
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Exploring A 213% Potential Upside - DirectorsTalk Interviews
ARS Pharmaceuticals receives European approval nod for children's nasal spray - Traders Union
Market Fear: Can ARS Pharmaceuticals Inc sustain earnings growth2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Returns Recap: Can ARS Pharmaceuticals Inc sustain earnings growthWeekly Stock Analysis & Reliable Price Breakout Signals - baoquankhu1.vn
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences - Investing News Network
ARS Pharmaceuticals Announces Conference Call and Webcast - GlobeNewswire
Upcoming ARS Pharma call on 2025 results plus March investor conferences - Stock Titan
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Nasus Pharma Is Targeting a Validated Market With a Potentially Superior Intranasal Delivery Approach - GuruFocus
Levin Capital Strategies L.P. Increases Holdings in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
CenterBook Partners LP Invests $5.15 Million in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
How Recent Regulatory Twists Are Reframing The Story For ARS Pharmaceuticals (SPRY) - Yahoo Finance
How Ars Pharmaceuticals Inc. (SPRY) Affects Rotational Strategy Timing - Stock Traders Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 7%Here's What Happened - MarketBeat
Practice Advances: A focus on neffy® (epinephrine nasal spray) - Patient Care Online
ARS Pharmaceuticals, Inc. $SPRY Shares Purchased by Aberdeen Group plc - MarketBeat
Got $300? 2 Biotech Stocks to Buy and Hold Forever - Yahoo Finance
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
What are ARS Pharmaceuticals Inc.’s earnings expectations2025 Risk Factors & Verified Momentum Stock Alerts - mfd.ru
Will ARS Pharmaceuticals Inc announce a stock splitTrade Volume Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Is ARS Pharmaceuticals Inc. stock vulnerable to regulatory risksSwing Trade & Weekly High Return Opportunities - mfd.ru
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock - Seeking Alpha
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates - MSN
Why hedge funds are buying ARS Pharmaceuticals Inc. stockJuly 2025 Reactions & High Win Rate Trade Alerts - mfd.ru
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® at 2026 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting - Investing News Network
Needle-free epinephrine nasal spray may cut costs and boost patient preference - Stock Titan
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting - Yahoo Finance
Why ARS Pharmaceuticals Inc. stock remains on watchlists2025 Macro Impact & Weekly Return Optimization Alerts - mfd.ru
Market Moves: Is INHDs ROE strong enoughWeekly Trend Summary & Precise Trade Entry Recommendations - baoquankhu1.vn
(SPRY) and the Role of Price-Sensitive Allocations - Stock Traders Daily
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Will ARS Pharmaceuticals Inc. stock recover after earningsWeekly Loss Report & Capital Efficiency Focused Ideas - mfd.ru
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Eyeing a 171% Upside with Innovative Allergy Solutions - DirectorsTalk Interviews
How Investors May Respond To ARS Pharmaceuticals (SPRY) Expanding EURneffy Pediatric Use Across Europe - Yahoo Finance
Aquestive leaps, despite receiving CRL for Anaphylm NDA - The Pharma Letter
ARS Pharma Gets Positive CHMP Opinion For 1 Mg EURneffy Nasal Spray - Nasdaq
Needle-free allergy rescue for kids wins key EU support - Stock Titan
US FDA declines to approve Aquestive's oral drug for allergic reactions - Reuters
EURneffy® 1 mg (adrenaline nasal spray) Recommended for - GlobeNewswire
Targets Report: Will OceanPal Inc benefit from geopolitical trendsCPI Data & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Lisanti Capital Growth LLC Sells 208,886 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Weekly Recap: Will ARS Pharmaceuticals Inc announce a stock splitJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
ARS Pharmaceuticals (NASDAQ:SPRY) Cut to Strong Sell at Zacks Research - MarketBeat
Ars Pharmaceuticals Inc (SPRY) 財務データ
収益
当期純利益
現金流量
EPS
0.50%
大文字化:
|
ボリューム (24 時間):